Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
AstraZeneca
Teva
Covington
Queensland Health
Cantor Fitzgerald
Cipla
Johnson and Johnson

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: RE42462

« Back to Dashboard

Which drugs does patent RE42462 protect, and when does it expire?

Patent RE42462 protects LETAIRIS and is included in one NDA.

This patent has sixty-two patent family members in thirty countries.
Summary for Patent: RE42462
Title:Carboxylic acid derivatives, their preparation and use
Abstract: Carboxylic acid derivatives ##STR00001## where R-R.sup.6, X, Y and Z have the meanings stated in the description, and the preparation thereof, are described. The novel compounds are suitable for controlling diseases.
Inventor(s): Riechers; Hartmut (Neustadt, DE), Klinge; Dagmar (Heidelberg, DE), Amberg; Wilhelm (Friedrichsdorf, DE), Kling; Andreas (Mannheim, DE), Muller; Stefan (Speyer, DE), Baumann; Ernst (Dudenhofen, DE), Rheinheimer; Joachim (Ludwigshafen, DE), Vogelbacher; Uwe Josef (Ludwigshafen, DE), Wernet; Wolfgang (Hassloch, DE), Unger; Liliane (Ludwigshafen, DE), Raschack; Manfred (Weisenheim, DE)
Assignee: Abbott GmbH & Co. KG (Wiesbaden, DE)
Application Number:12/481,594
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent RE42462
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent RE42462

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Gilead LETAIRIS ambrisentan TABLET;ORAL 022081-001 Jun 15, 2007 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Gilead LETAIRIS ambrisentan TABLET;ORAL 022081-002 Jun 15, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: RE42462

PCT Information
PCT FiledOctober 07, 1995PCT Application Number:PCT/EP95/03963
PCT Publication Date:April 25, 1996PCT Publication Number: WO96/11914

Non-Orange Book US Patents Family Members for Patent RE42462

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,119,097 Carboxylic acid derivatives, their preparation and their use ➤ Sign Up
5,969,134 Carboxylic acid derivatives, their preparation and use ➤ Sign Up
5,772,589 Measurement process for blood gas analysis sensors ➤ Sign Up
7,109,205 Carboxylic acid derivatives, their preparation and use ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Medtronic
US Army
Accenture
Teva
Farmers Insurance
US Department of Justice
Fish and Richardson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.